A Phase 3 interventional study of Insulin Lispro Protamine Suspension and Insulin Glargine in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 52 sites in 2 countries. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2011-01-13.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing Insulin Lispro in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. Insulin Lispro · Diabetes Mellitus, Type 2.
Among the 36 studies testing Insulin Lispro in Diabetes Mellitus, Type 2, this one is the 12th largest by enrollment, is one of 5 that started in 2007, is one of 9 in phase 3, and was the 8th registered.
10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →None of the 36 studies testing Insulin Lispro in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →
Insulin Lispro: first FDA approval 1996 (HUMALOG KWIKPEN), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 5 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 339 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 127 across the 36 interventional studies. Of the 34 that completed or were terminated, 28 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 36 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 154 are open to participants now.
Of its 541 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 87th largest by enrollment of the 232 interventional ones that give a count, is one of 9 that started in 2007, is one of 85 in phase 3, and was the 28th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 36 studies testing Insulin Lispro in Diabetes Mellitus, Type 2, from their registry updates:
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This study will compare insulin lispro protamine suspension (ILPS) and insulin glargine in combination with the patient's oral diabetes medications and exenatide, for their ability to control blood sugar in patients with type 2 diabetes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Insulin Lispro Protamine Suspension (ILPS)
Drug: Insulin Lispro Protamine Suspension
Insulin Glargine
Drug: Insulin Glargine
Administered subcutaneously once a day at bedtime
Also known as: LY275585[P]
Administered subcutaneously once a day at bedtime
Also known as: Lantus
Change From Baseline in Hemoglobin A1C (HbA1c) at Endpoint (Last Observation Carried Forward [LOCF])
Least squares mean values were controlled for Baseline + Baseline HbA1c Group + Baseline sulfonylurea (SU) Group.
Time frame: Baseline, Endpoint (LOCF) up to 24 weeks
Actual Hemoglobin A1C at 24 Weeks and Endpoint (LOCF)
Least squares mean values were controlled for Baseline + Baseline HbA1c Group + Baseline SU Group.
Time frame: 24 weeks, Endpoint (LOCF) up to 24 weeks
Change From Baseline in Hemoglobin A1C at 24 Weeks and Endpoint (LOCF)
Least squares mean values were controlled for Baseline + Baseline HbA1c Group + Baseline SU Group.
Time frame: Baseline, 24 Weeks, Endpoint (LOCF) up to 24 weeks
Percentage of Participants With Hemoglobin A1C Less Than 7.0% and Hemoglobin A1C Less Than or Equal to 6.5%
Time frame: Weeks 12, 18, 24 and Endpoint (LOCF) up to 24 weeks
7-Point Self-Monitored Blood Glucose (SMBG) Profiles at Baseline and Endpoint (LOCF)
SMBG at morning pre-meal, morning post-prandial, midday pre-meal, midday post-prandial, evening pre-meal, evening postprandial, 0300 hours. Post-prandial glucose is measured 2 hours after the start of the meal.
Time frame: Baseline, Endpoint (LOCF) up to 24 weeks
Glycemic Variability at Baseline and Endpoint (LOCF)
Glycemic variability was defined as the standard deviation (SD) of a participant's intra-day 7-point, self-monitored, blood glucose. Mean SD was calculated based on the SD for each participant in the study.
Time frame: Baseline, Endpoint (LOCF) up to 24 weeks
Incidence of Self-reported Hypoglycemic Episodes (All, Non-Nocturnal, Nocturnal, and Severe)
Overall:any time after randomization.Episode:any time patient experienced sign/symptom associated with hypoglycemia, or had blood glucose level ≤70 mg/dL. Non-nocturnal:any episode that occurred between waking and bedtime. Nocturnal:any episode that occurred between bedtime and waking.Severe:episode with symptoms consistent with neuroglycopenia in which patient requires assistance,and is associated with:blood glucose value \<50 mg/dL or prompt recovery after oral carbohydrate, glucagon, or intravenous glucose.Incidence(%)=(Number of patients experiencing episodes/number of patients in arm)\*100.
Time frame: Baseline to Endpoint (LOCF) up to 24 weeks
Rate of All, Non-Nocturnal, and Nocturnal Self-Reported Hypoglycemic Episodes (Adjusted for One Year)
Rate of self-reported hypoglycemic episodes, all, non-nocturnal, and nocturnal, at Endpoint (LOCF) and overall. Rate is reported as episodes/participant/365 days. Episode = any time participant feels that he/she is experiencing a sign or symptom that is associated with hypoglycemia or has a blood glucose level of ≤70 mg/dL, even if it was not associated with signs, symptoms, or treatment. Overall=any time during the post-randomization visits within the study period. Nocturnal=Any episode that occurs between bedtime and waking. Non-Nocturnal=Any episode that occurs between waking and bedtime.
Time frame: Baseline to Endpoint (LOCF) up to 24 weeks
Actual Body Weight at Baseline and Endpoint (LOCF)
Time frame: Baseline, Endpoint (LOCF) up to 24 weeks
Change From Baseline in Body Weight at Endpoint (LOCF)
Time frame: Baseline, Endpoint (LOCF) up to 24 weeks
Total Daily Insulin Dose at Endpoint (LOCF)
Time frame: Endpoint (LOCF) up to 24 weeks
| Milestone | ILPS | Glargine |
|---|---|---|
| Started | 171 | 168 |
| Intention to treat (itt) population | 170 | 167 |
| Completed | 154 | 151 |
| Not completed | 17 | 17 |
| Withdrew: Adverse event | 3 | 2 |
| Withdrew: Entry criteria not met | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Physician decision | 2 | 6 |
| Withdrew: Protocol violation | 6 | 5 |
| Withdrew: Sponsor decision | 2 | 0 |
| Withdrew: Withdrawal by subject | 3 | 3 |
Least squares mean values were controlled for Baseline + Baseline HbA1c Group + Baseline sulfonylurea (SU) Group.
| percent of glycosylated hemoglobin | ILPS | Glargine |
|---|---|---|
| Baseline | 8.48 ± 0.04 | 8.47 ± 0.04 |
| Endpoint (LOCF) Change | -1.21 ± 0.07 | -1.43 ± 0.07 |
Least squares mean values were controlled for Baseline + Baseline HbA1c Group + Baseline SU Group.
| percent of glycosylated hemoglobin | ILPS | Glargine |
|---|---|---|
| 24 weeks | 6.94 ± 0.07 | 6.70 ± 0.06 |
| Endpoint (LOCF) | 7.00 ± 0.07 | 6.78 ± 0.07 |
Least squares mean values were controlled for Baseline + Baseline HbA1c Group + Baseline SU Group.
| percent of glycosylated hemoglobin | ILPS | Glargine |
|---|---|---|
| Baseline | 8.48 ± 0.04 | 8.47 ± 0.04 |
| 24 Weeks Change | -1.25 ± 0.07 | -1.49 ± 0.06 |
| Endpoint (LOCF) Change | -1.21 ± 0.07 | -1.43 ± 0.07 |
| percent of participants | ILPS | Glargine |
|---|---|---|
| Week 12: HbA1c <7.0% | 46.9 | 50.7 |
| Week 12: HbA1c <=6.5% | 24.8 | 28.7 |
| Week 18: HbA1c <7.0% | 54.8 | 69.1 |
| Week 18: HbA1c <=6.5% | 30.8 | 37.6 |
| Week 24: HbA1c <7.0% | 55.4 | 63.4 |
| Week 24: HbA1c <=6.5% | 29.7 | 39.9 |
| Endpoint (LOCF): HbA1c <7.0% | 53.7 | 61.7 |
| Endpoint (LOCF): HbA1c <=6.5% | 28.4 | 38.9 |
SMBG at morning pre-meal, morning post-prandial, midday pre-meal, midday post-prandial, evening pre-meal, evening postprandial, 0300 hours. Post-prandial glucose is measured 2 hours after the start of the meal.
| milligrams per deciliter (mg/dL) | ILPS | Glargine |
|---|---|---|
| Baseline Morning Pre-Meal | 175.41 ± 39.54 | 180.86 ± 38.95 |
| Baseline Morning Postprandial | 195.31 ± 54.65 | 190.84 ± 54.95 |
| Baseline Midday Pre-Meal | 165.18 ± 43.51 | 166.34 ± 47.64 |
| Baseline Midday Postprandial | 193.22 ± 46.95 | 200.25 ± 54.64 |
| Baseline Evening Pre-Meal | 173.33 ± 44.60 | 175.14 ± 43.35 |
| Baseline Evening Postprandial | 189.00 ± 49.62 | 184.92 ± 49.42 |
| Baseline 0300 Hours | 170.51 ± 43.44 | 172.00 ± 39.10 |
| Baseline Daily Mean 7-Point Blood Glucose | 180.19 ± 36.95 | 180.72 ± 38.17 |
| Baseline Daily Mean Pre-Meal | 170.60 ± 36.06 | 172.66 ± 38.60 |
| Baseline Daily Mean Postprandial | 192.37 ± 41.48 | 191.27 ± 46.11 |
| Endpoint Morning Pre-Meal | 129.63 ± 31.58 | 127.01 ± 29.08 |
| Endpoint Morning Postprandial | 152.32 ± 44.81 | 137.39 ± 36.65 |
| Endpoint Midday Pre-Meal | 132.84 ± 36.63 | 129.71 ± 34.34 |
| Endpoint Midday Postprandial | 161.77 ± 42.46 | 155.26 ± 37.86 |
| Endpoint Evening Pre-Meal | 146.03 ± 37.93 | 135.93 ± 33.79 |
| Endpoint Evening Postprandial | 159.14 ± 45.35 | 144.25 ± 34.17 |
| Endpoint 0300 Hours | 123.96 ± 35.45 | 127.53 ± 30.90 |
| Endpoint Daily Mean 7-Point Blood Glucose | 143.06 ± 30.00 | 136.17 ± 25.65 |
| Endpoint Daily Mean Pre-Meal | 135.51 ± 30.39 | 129.32 ± 26.54 |
| Endpoint Daily Mean Postprandial | 158.10 ± 36.81 | 146.12 ± 30.37 |
Glycemic variability was defined as the standard deviation (SD) of a participant's intra-day 7-point, self-monitored, blood glucose. Mean SD was calculated based on the SD for each participant in the study.
| mg/dL | ILPS | Glargine |
|---|---|---|
| Baseline | 41.15 ± 13.69 | 39.02 ± 13.52 |
| Endpoint | 36.78 ± 16.02 | 30.96 ± 13.24 |
Overall:any time after randomization.Episode:any time patient experienced sign/symptom associated with hypoglycemia, or had blood glucose level ≤70 mg/dL. Non-nocturnal:any episode that occurred between waking and bedtime. Nocturnal:any episode that occurred between bedtime and waking.Severe:episode with symptoms consistent with neuroglycopenia in which patient requires assistance,and is associated with:blood glucose value \<50 mg/dL or prompt recovery after oral carbohydrate, glucagon, or intravenous glucose.Incidence(%)=(Number of patients experiencing episodes/number of patients in arm)\*100.
| percentage of participants | ILPS | Glargine |
|---|---|---|
| All Reported - Endpoint | 41.8 | 43.1 |
| All Reported - Overall | 70.6 | 74.9 |
| Non-Nocturnal - Endpoint | 30.6 | 40.1 |
| Non-Nocturnal - Overall | 62.4 | 70.7 |
| Nocturnal - Endpoint | 21.8 | 11.4 |
| Nocturnal - Overall | 47.6 | 37.1 |
| Severe - Endpoint | 0 | 0 |
| Severe - Overall | 1.8 | 0 |
Rate of self-reported hypoglycemic episodes, all, non-nocturnal, and nocturnal, at Endpoint (LOCF) and overall. Rate is reported as episodes/participant/365 days. Episode = any time participant feels that he/she is experiencing a sign or symptom that is associated with hypoglycemia or has a blood glucose level of ≤70 mg/dL, even if it was not associated with signs, symptoms, or treatment. Overall=any time during the post-randomization visits within the study period. Nocturnal=Any episode that occurs between bedtime and waking. Non-Nocturnal=Any episode that occurs between waking and bedtime.
| episodes/participant/365 days | ILPS | Glargine |
|---|---|---|
| All reported episodes rate - Endpoint | 14.51 ± 27.75 | 15.29 ± 29.73 |
| All reported episodes rate - Overall | 16.27 ± 23.19 | 18.05 ± 24.59 |
| Non-Nocturnal reported episodes rate - Endpoint | 10.40 ± 23.46 | 13.20 ± 28.01 |
| Non-Nocturnal reported episodes rate - Overall | 11.36 ± 19.16 | 14.83 ± 21.00 |
| Nocturnal reported episodes rate - Endpoint | 4.01 ± 9.73 | 1.73 ± 5.53 |
| Nocturnal reported episodes rate - Overall | 4.88 ± 8.43 | 3.01 ± 7.21 |
| kilograms | ILPS | Glargine |
|---|---|---|
| Baseline | 101.57 ± 18.67 | 102.62 ± 19.58 |
| Endpoint | 101.85 ± 18.91 | 103.28 ± 19.42 |
| kilograms | ILPS | Glargine |
|---|---|---|
| Change From Baseline in Body Weight at Endpoint (LOCF) | 0.27 ± 3.38 | 0.66 ± 3.93 |
| Units of Insulin | ILPS | Glargine |
|---|---|---|
| Total Daily Insulin Dose at Endpoint (LOCF) | 31.11 ± 18.87 | 37.93 ± 18.46 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ILPS | — | 9/170 (5.3%) | 96/170 (56.5%) |
| Glargine | — | 5/167 (3%) | 115/167 (68.9%) |
| Event | ILPS | Glargine |
|---|---|---|
| Atrial fibrillationCardiac disorders | 2/170 | 0/167 |
| Chest painGeneral disorders | 0/170 | 1/167 |
| CholelithiasisHepatobiliary disorders | 0/170 | 1/167 |
| Ankle fractureInjury, poisoning and procedural complications | 0/170 | 1/167 |
| Drug exposure during pregnancyInjury, poisoning and procedural complications | 0/170 | 1/167 |
| FallInjury, poisoning and procedural complications | 0/170 | 1/167 |
| Heat exhaustionInjury, poisoning and procedural complications | 0/170 | 1/167 |
| AppendicitisInfections and infestations | 1/170 | 0/167 |
| Cystitis bacterialInfections and infestations | 1/170 | 0/167 |
| Pneumonia pneumococcalInfections and infestations | 1/170 | 0/167 |
| Event | ILPS | Glargine |
|---|---|---|
| HeadacheNervous system disorders | 11/170 | 15/167 |
| NauseaGastrointestinal disorders | 13/170 | 10/167 |
| DiarrhoeaGastrointestinal disorders | 11/170 | 12/167 |
| Gastroenteritis viralInfections and infestations | 2/170 | 12/167 |
| NasopharyngitisInfections and infestations | 12/170 | 9/167 |
| Upper respiratory tract infectionInfections and infestations | 11/170 | 10/167 |
| SinusitisInfections and infestations | 7/170 | 9/167 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 3/170 | 9/167 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 9/170 | 7/167 |
| VomitingGastrointestinal disorders | 6/170 | 8/167 |
| Age Continuous(years) | ILPS | Glargine | Total |
|---|---|---|---|
| Mean | 56.51 ± 9.73 | 56.24 ± 9.33 | 56.38 ± 9.52 |
| Sex: Female, Male(Participants) | ILPS | Glargine | Total |
|---|---|---|---|
| Female | 95 | 75 | 170 |
| Male | 76 | 93 | 169 |
| Race/Ethnicity, Customized(participants) | ILPS | Glargine | Total |
|---|---|---|---|
| Black or African American | 13 | 14 | 27 |
| East Asian | 5 | 6 | 11 |
| Hispanic | 21 | 17 | 38 |
| Native American | 0 | 1 | 1 |
| West Asian (Indian sub-continent) | 2 | 0 | 2 |
| White | 130 | 130 | 260 |
| Region of Enrollment(participants) | ILPS | Glargine | Total |
|---|---|---|---|
| United States | 165 | 165 | 330 |
| Puerto Rico | 6 | 3 | 9 |
| Body Mass Index(kilograms/square meters (kg/m^2)) | ILPS | Glargine | Total |
|---|---|---|---|
| Mean | 34.92 ± 5.21 | 34.78 ± 5.17 | 34.85 ± 5.18 |
| Body Weight(Kilograms) | ILPS | Glargine | Total |
|---|---|---|---|
| Mean | 101.57 ± 18.67 | 102.33 ± 19.73 | 101.95 ± 19.18 |
| Hemoglobin A1C(percent of glycosylated hemoglobin) | ILPS | Glargine | Total |
|---|---|---|---|
| Mean | 8.21 ± 0.79 | 8.22 ± 0.80 | 8.22 ± 0.79 |
| Sulfonylurea Group(participants) | ILPS | Glargine | Total |
|---|---|---|---|
| Yes | 108 | 110 | 218 |
| No | 63 | 58 | 121 |
1 further baseline measures are reported on the registry.
The record gives a start of Nov 2007, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2010, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin Lispro · Insulin Glargine